AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
Highlights
- Health-imaging software drew growth attention as strong earnings and fresh contract wins reinforced a premium franchise.
- Pro Medicus anchored the theme, pairing rapid revenue growth with a run of new hospital agreements.
- Radiopharmaceutical names Telix and Clarity rounded out a healthcare growth cohort tied to structural demand.
Pro Medicus Ltd (ASX:PME) stayed in focus on the local market today as the health-imaging software major reinforced its place at the front of the ASX healthcare growth cohort. The company recently delivered a standout first-half result, with underlying earnings and revenue both expanding at a rapid clip on the back of a run of sizeable new hospital contract wins.
Health imaging as a structural growth theme
Healthcare has long been a fertile hunting ground for growth because the underlying demand drivers barely flex with the economic cycle. Ageing populations, rising diagnostic volumes and the steady digitisation of medical records create a long runway for the software and specialist companies that serve the sector. That structural quality is what sets healthcare growth apart from the more cyclical stories elsewhere on the board.
Health-imaging software sits at the sharp end of that theme. As hospitals move to cloud-based systems that let clinicians view and share complex scans instantly, the vendors with the fastest, most reliable platforms stand to capture a growing share of a large global market. That is the backdrop against which the market kept its focus on the imaging leader today, even as the wider healthcare cohort traded quietly.
Pro Medicus and the premium franchise
The imaging-software major has built a reputation as a best-in-class operator, winning long-term contracts with major hospital networks and converting them into high-margin, recurring revenue. Its recent first-half result underscored the momentum, with underlying earnings and revenue both climbing sharply and a fresh batch of contract wins swelling the order book. That combination of growth and profitability is rare, and it is why the franchise commands a premium rating.
The premium is also the catch. A richly valued share leaves little room for disappointment, and any stumble in growth or contract momentum could prompt a sharp reappraisal. The market treats the company as a quality compounder with a long runway, but the elevated multiple means expectations are high, and holders are effectively paying today for a great deal of future growth that must still be delivered.
Telix Pharmaceuticals (ASX:TLX) and the radiopharma push
Radiopharmaceutical group Telix Pharmaceuticals brings a different flavour of healthcare growth, developing imaging and therapy products that use targeted radiation to detect and treat cancer. The company has built a commercial franchise around its diagnostic agents and is pushing a pipeline of therapeutic candidates that could open far larger markets if they clear regulatory and clinical hurdles.
Clarity Pharmaceuticals (ASX:CU6) and the diagnostics pipeline
Clinical-stage group Clarity Pharmaceuticals rounds out the healthcare trio with a focus on next-generation radiopharmaceutical products for diagnosis and therapy. As an earlier-stage name, its story rests more on clinical progress than on current revenue, which gives it a higher-risk, higher-reward profile than the established imaging and commercial players.
Why healthcare growth resists the rate cycle
Healthcare growth names carry the same long-duration profile as technology, which in theory should make them sensitive to rising bond yields. Yet the sector often proves more resilient because its demand drivers are so defensive. People need diagnostics and treatment regardless of the economic backdrop, and that steady demand gives healthcare earnings a floor that few other growth cohorts can match.
Recurring revenue and the compounding effect
The most valued healthcare growth names share a common trait: recurring, high-margin revenue that compounds over time. The imaging-software leader converts long-term hospital contracts into predictable income streams, and each new win adds to a base that keeps generating cash for years. That compounding is the engine behind the premium the market is willing to pay.
The radiopharmaceutical opportunity
Radiopharmaceuticals have emerged as one of the most closely watched corners of the healthcare growth story. By pairing targeted radiation with molecules that seek out diseased tissue, the field promises more precise diagnosis and treatment, and a wave of clinical and commercial progress has drawn fresh attention to the local names pursuing it. That momentum has lifted the profile of the whole sub-sector.
Growth at a price versus growth at a discount
The healthcare growth cohort spans a wide range of valuations, from the premium-rated imaging leader to the earlier-stage biotech names whose worth rests on future milestones. That spread reflects the market's attempt to price both the quality of the earnings and the certainty of their delivery, and it means the growth label covers very different risk profiles within a single sector.
Operational execution, disciplined capital management and clear project delivery remain central as the Australian market continues assessing this part of the listed sector.
